MedTrace Logo

Losartan and Emotional Processing in Young People

NCT06636812 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-15

No results posted yet for this study

Summary

This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.

Conditions

  • Emotional Processing

Interventions

DRUG

Losartan potassium

Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo

OTHER

Placebo

Single tablet encapsulated identically to placebo

Sponsors & Collaborators

  • Oxford Health Biomedical Research Centre (OH BRC) support scheme

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Principal Investigators

  • Andrea Reinecke, PhD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-07
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06636812 on ClinicalTrials.gov